Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06344052 · ClinicalTrials.gov registry record · Phase 2
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
A Phase 2 study of Basal Cell Carcinoma, sponsored by Stamford Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 10
- Study locations
NCT06344052: Recruiting Phase 2 study of Basal Cell Carcinoma, sponsored by Stamford Pharmaceuticals.
NCT06344052 is a Phase 2 study of Basal Cell Carcinoma that is actively recruiting participants, run by Stamford Pharmaceuticals. The registered enrollment target is 80 participants, below the 101-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (21% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06344052, a Phase 2 study of Basal Cell Carcinoma, is actively recruiting participants, sponsored by Stamford Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 10
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receive daily hedgehog pathway inhibitor only.
Primary Outcome
ORR defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) of the target lesion based on central review at any time point.
Conditions Studied
Interventions
- DRUG Vismodegib
- DRUG SP-002
Study Locations (10)
Florida
- Research Site - Boca Raton
- Research Site - Coral Springs
- Research Site - Cutler Bay
Texas
- Research Site - Cedar Park
- Research Site - Humble
- Research Site - Longview
Arizona
- Research Site - Phoenix
Maryland
- Research Site - Rockville
Missouri
- Research Site - Lee's Summit
New York
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
What NCT06344052 shows while recruiting
NCT06344052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 101-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT06344052 lists 10 locations in 6 states (Florida, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT06344052 about?
NCT06344052 is a clinical study titled "To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma". The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an ...
What is the current status of trial NCT06344052?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-04-09. Estimated completion is 2029-03-30.
What conditions does trial NCT06344052 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT06344052?
The interventions under investigation include: Vismodegib (DRUG), SP-002 (DRUG).
Who is sponsoring clinical trial NCT06344052?
This trial is sponsored by Stamford Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06344052 being conducted?
This trial has 10 study locations across Arizona, Florida, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06344052's enrollment target sits among peer trials
80 6th of 24 higher than 19 of 24 other Basal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Basal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
RECRUITING · Phase 2
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Photochemical Tissue Bonding
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI